The Global Health Body Raises Warning Over Severe Shortage of Obesity Jabs
Less than one in 10 individuals who could benefit from weight-loss injections including Wegovy are able to get them, warns the global health agency as it issues its initial guidance on the drugs.
With in excess of 1,000,000,000 people worldwide currently obese, it is calling for more widespread and fairer access to GLP-1 medication.
According to projections, more than two billion will be living with obesity by 2030 if no action is taken.
"Our new guidelines affirms that obesity is a long-term condition that can be treated with comprehensive and continuous treatment," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and supply-chain constraints are key obstacles to universal availability to the treatments that can help people shift substantial body mass, notes the body.
Weight-Loss Drug Scarcity
Even under the current most optimistic scenario, the production of these medications would only suffice for around 100 million people – under 10% of eligible patients, per the health organization.
The recommendation urges nations and manufacturers to increase access, via measures including patent sharing.
A patent on a key compound – the primary ingredient of Novo Nordisk's Wegovy – is scheduled to end in multiple nations in 2026.
How Obesity Injections Function
GLP-1 drugs replicate a biological compound to reduce digestion speed, reduce hunger and enhance the sense of being full so users reduce food intake.
People commonly see weight reduction after several weeks of beginning the weekly injections.
Evidence indicates users may see weight return after a year of halting the medication, as their usual appetite return.
Being overweight or obese raises your risk for contracting health problems, like diabetes, heart disease, stroke, and some malignancies.
Excess weight affects individuals in all nations and was responsible for over three and a half million fatalities worldwide in 2024, as per the WHO.
